Cancer cells with RET/PTC1 rearrangements rely more on the RAF‐1 pathway for survival and growth than on the BRAF‐ERK pathway, which is typically needed in cells with RAS or BRAF mutations [61]. This evidence concerns the gene RET and cancer.